Phase 2 Eczema Trial, Recruiting NCT07003425 Sponsor: Apogee Therapeutics, Inc. Condition: Eczema
Back to Eczema

Phase 2 Eczema Trial, Recruiting

NCT07003425
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have already completed the full treatment period in a previous APG777 study, and the study doctor must feel you followed the study rules properly
  • The study doctor must believe that continuing treatment with APG777 for a longer period of time would be beneficial for you
  • You must be willing to use the same over-the-counter, non-medicated moisturizer or lotion you were using at the end of the previous study, throughout this new study

Who may not be able to join:

  • If you experienced a side effect during the previous APG777 study that the study doctor or medical overseer believes makes it too risky for you to continue taking APG777, you may not be eligible
  • If you left the previous APG777 study early, or if your study medication was permanently stopped during that study, you would not be eligible
  • If you are taking any medications that are not allowed by this study's guidelines at the time of your first appointment, you may not be eligible
  • If you have any skin conditions or other health conditions (besides the one being studied) that could make it difficult to accurately assess your skin or could interfere with the study results, you may not be eligible

Important: Always verify eligibility with the trial site directly before applying.

Note: There may be additional eligibility requirements not listed here — the trial site can provide the full details.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 7812082408

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Apogee Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
14 May 2025
Est. completion
1 December 2029

Where this trial is recruiting

🇨🇦 Canada 🇨🇿 Czechia 🇩🇪 Germany 🇭🇺 Hungary 🇵🇱 Poland 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of Participants with Treatment Emergent Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov